ArticleInternational journal of hepatology2025

Adverse Reactions of First-Line Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma Treatment: A Descriptive Analysis From WHO-VigiAccess.

Wei Fan Sui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.